SCHEMBL5161502

SCHEMBL5161502

C=CCn1c(-c2ccco2)nc2c(N)nc(SCCc3ccccc3)nc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 10/20 0.51
ADORA2A P29274 10/20 0.51
ADORA2B P29275 8/20 0.51
TMIGD3 P0DMS9 5/20 0.51
ADORA3 P0DMS8 5/20 0.44
CASR P41180 1/20 0.41
ABCB1 P08183 1/20 0.41
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
KDM4E B2RXH2 2/20 0.41
HSD17B10 Q99714 2/20 0.41
GAA P10253 2/20 0.41
NPC1 O15118 1/20 0.41
USP2 O75604 1/20 0.41
GLA P06280 1/20 0.41
POLB P06746 1/20 0.41
HPGD P15428 1/20 0.41
CASP1 P29466 1/20 0.41
RAB9A P51151 1/20 0.41
CASP7 P55210 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5161094 0.95 ADORA2A (0.51) ADORA1ADORA2AADORA2BTMIGD3ADORA3
SCHEMBL5178361 0.88 ADORA2A (0.59) ADORA1ADORA2AADORA2BTMIGD3ADORA3
SCHEMBL5160279 0.85 ADORA1 (0.51) ADORA1ADORA2AADORA2BTMIGD3ADORA3
SCHEMBL5162984 0.85 ADORA1 (0.53) ADORA1ADORA2AADORA2BTMIGD3ADORA3
SCHEMBL5163815 0.83 ADORA2A (0.59) ADORA1ADORA2AADORA2BTMIGD3ADORA3
SCHEMBL5160437 0.83 ADORA2A (0.61) ADORA1ADORA2AADORA2BTMIGD3ADORA3
SCHEMBL5161406 0.83 ADORA1 (0.51) ADORA1ADORA2AADORA2BTMIGD3ADORA3
SCHEMBL5161297 0.82 ADORA2A (0.60) ADORA1ADORA2AADORA2BTMIGD3ADORA3
SCHEMBL5161872 0.82 ADORA2A (0.56) ADORA1ADORA2AADORA2BTMIGD3ADORA3
SCHEMBL5161362 0.82 ADORA1 (0.51) ADORA1ADORA2AADORA2BTMIGD3ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7189730-B2 A2A adenosine receptor antagonists CV THERAPEUTICS, INC. (US) 2007-03-13 US disclosed
EP-1456209-B1 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS INC (US) 2007-02-28 EP disclosed
US-20030149060-A1 A2A adenosine receptor antagonists CV THERAPEUTICS, INC. 2003-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149060-A1 A2A adenosine receptor antagonists ADORA2A, ADORA2B, ADORA3 ADORA1 4/4885ADORA2A 1/4885ADORA2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.